Genomic and epigenomic signatures in ovarian cancer associated with resensitization to platinum drugs

Fang Fang, Horacio Cardenas, Hao Huang, Guanglong Jiang, Susan Perkins, Chi Zhang, Harold N. Keer, Yunlong Liu, Kenneth Nephew, Daniela Matei

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

DNA methylation aberrations have been implicated in acquired resistance to platinum drugs in ovarian cancer. In this study, we elucidated an epigenetic signature associated with platinum drug resensitization that may offer utility in predicting the outcomes of patients who are coadministered a DNA methyltransferase inhibitor. The ovarian cancer specimens we analyzed were derived from a recent clinical trial that compared the responses of patients with recurrent platinum-resistant ovarian cancer who received carboplatin plus the DNA methyltransferase inhibitor guadecitabine or a standard-of-care chemotherapy regimen selected by the treating physician. Tumor biopsies or malignant ascites were collected from patients before treatment (day 1, cycle 1) or after treatment (after 2 cycles) for epigenomic and transcriptomic profiling using the Infinium HumanMethyla-tion450 BeadChip (HM450). We defined 94 gene promoters that were hypomethylated significantly by guadecitabine, with 1,659 genes differentially expressed in pretreatment versus posttreatment tumors. Pathway analysis revealed that the experimental regimen significantly altered immune reactivation and DNA repair pathways. Progression-free survival correlated with baseline expression levels of 1,155 genes involved in 25 networks. In functional investigations in ovarian cancer cells, engineered upregulation of certain signature genes silenced by promoter methylation (DOK2, miR-193a, and others) restored platinum drug sensitivity. Overall, our findings illuminate how inhibiting DNA methylation can sensitize ovarian cancer cells to platinum drugs, in large part by altering gene expression patterns related to DNA repair and immune activation, with implications for improving the personalized care and survival outcomes of ovarian cancer patients. Significance: Epigenomic targeting may improve therapeutic outcomes in platinum-resistant and recurrent ovarian cancer in part by effects on DNA repair and antitumor immune responses.

Original languageEnglish (US)
Pages (from-to)631-644
Number of pages14
JournalCancer Research
Volume78
Issue number3
DOIs
StatePublished - Feb 1 2018

Fingerprint

Platinum
Epigenomics
Ovarian Neoplasms
Pharmaceutical Preparations
DNA Repair
Methyltransferases
DNA Methylation
Genes
Carboplatin
DNA
Standard of Care
Ascites
Methylation
Disease-Free Survival
Neoplasms
Up-Regulation
Therapeutics
Clinical Trials
Physicians
Biopsy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Genomic and epigenomic signatures in ovarian cancer associated with resensitization to platinum drugs. / Fang, Fang; Cardenas, Horacio; Huang, Hao; Jiang, Guanglong; Perkins, Susan; Zhang, Chi; Keer, Harold N.; Liu, Yunlong; Nephew, Kenneth; Matei, Daniela.

In: Cancer Research, Vol. 78, No. 3, 01.02.2018, p. 631-644.

Research output: Contribution to journalArticle

Fang, Fang ; Cardenas, Horacio ; Huang, Hao ; Jiang, Guanglong ; Perkins, Susan ; Zhang, Chi ; Keer, Harold N. ; Liu, Yunlong ; Nephew, Kenneth ; Matei, Daniela. / Genomic and epigenomic signatures in ovarian cancer associated with resensitization to platinum drugs. In: Cancer Research. 2018 ; Vol. 78, No. 3. pp. 631-644.
@article{53ceeba8ddf349098212374c02f714a9,
title = "Genomic and epigenomic signatures in ovarian cancer associated with resensitization to platinum drugs",
abstract = "DNA methylation aberrations have been implicated in acquired resistance to platinum drugs in ovarian cancer. In this study, we elucidated an epigenetic signature associated with platinum drug resensitization that may offer utility in predicting the outcomes of patients who are coadministered a DNA methyltransferase inhibitor. The ovarian cancer specimens we analyzed were derived from a recent clinical trial that compared the responses of patients with recurrent platinum-resistant ovarian cancer who received carboplatin plus the DNA methyltransferase inhibitor guadecitabine or a standard-of-care chemotherapy regimen selected by the treating physician. Tumor biopsies or malignant ascites were collected from patients before treatment (day 1, cycle 1) or after treatment (after 2 cycles) for epigenomic and transcriptomic profiling using the Infinium HumanMethyla-tion450 BeadChip (HM450). We defined 94 gene promoters that were hypomethylated significantly by guadecitabine, with 1,659 genes differentially expressed in pretreatment versus posttreatment tumors. Pathway analysis revealed that the experimental regimen significantly altered immune reactivation and DNA repair pathways. Progression-free survival correlated with baseline expression levels of 1,155 genes involved in 25 networks. In functional investigations in ovarian cancer cells, engineered upregulation of certain signature genes silenced by promoter methylation (DOK2, miR-193a, and others) restored platinum drug sensitivity. Overall, our findings illuminate how inhibiting DNA methylation can sensitize ovarian cancer cells to platinum drugs, in large part by altering gene expression patterns related to DNA repair and immune activation, with implications for improving the personalized care and survival outcomes of ovarian cancer patients. Significance: Epigenomic targeting may improve therapeutic outcomes in platinum-resistant and recurrent ovarian cancer in part by effects on DNA repair and antitumor immune responses.",
author = "Fang Fang and Horacio Cardenas and Hao Huang and Guanglong Jiang and Susan Perkins and Chi Zhang and Keer, {Harold N.} and Yunlong Liu and Kenneth Nephew and Daniela Matei",
year = "2018",
month = "2",
day = "1",
doi = "10.1158/0008-5472.CAN-17-1492",
language = "English (US)",
volume = "78",
pages = "631--644",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Genomic and epigenomic signatures in ovarian cancer associated with resensitization to platinum drugs

AU - Fang, Fang

AU - Cardenas, Horacio

AU - Huang, Hao

AU - Jiang, Guanglong

AU - Perkins, Susan

AU - Zhang, Chi

AU - Keer, Harold N.

AU - Liu, Yunlong

AU - Nephew, Kenneth

AU - Matei, Daniela

PY - 2018/2/1

Y1 - 2018/2/1

N2 - DNA methylation aberrations have been implicated in acquired resistance to platinum drugs in ovarian cancer. In this study, we elucidated an epigenetic signature associated with platinum drug resensitization that may offer utility in predicting the outcomes of patients who are coadministered a DNA methyltransferase inhibitor. The ovarian cancer specimens we analyzed were derived from a recent clinical trial that compared the responses of patients with recurrent platinum-resistant ovarian cancer who received carboplatin plus the DNA methyltransferase inhibitor guadecitabine or a standard-of-care chemotherapy regimen selected by the treating physician. Tumor biopsies or malignant ascites were collected from patients before treatment (day 1, cycle 1) or after treatment (after 2 cycles) for epigenomic and transcriptomic profiling using the Infinium HumanMethyla-tion450 BeadChip (HM450). We defined 94 gene promoters that were hypomethylated significantly by guadecitabine, with 1,659 genes differentially expressed in pretreatment versus posttreatment tumors. Pathway analysis revealed that the experimental regimen significantly altered immune reactivation and DNA repair pathways. Progression-free survival correlated with baseline expression levels of 1,155 genes involved in 25 networks. In functional investigations in ovarian cancer cells, engineered upregulation of certain signature genes silenced by promoter methylation (DOK2, miR-193a, and others) restored platinum drug sensitivity. Overall, our findings illuminate how inhibiting DNA methylation can sensitize ovarian cancer cells to platinum drugs, in large part by altering gene expression patterns related to DNA repair and immune activation, with implications for improving the personalized care and survival outcomes of ovarian cancer patients. Significance: Epigenomic targeting may improve therapeutic outcomes in platinum-resistant and recurrent ovarian cancer in part by effects on DNA repair and antitumor immune responses.

AB - DNA methylation aberrations have been implicated in acquired resistance to platinum drugs in ovarian cancer. In this study, we elucidated an epigenetic signature associated with platinum drug resensitization that may offer utility in predicting the outcomes of patients who are coadministered a DNA methyltransferase inhibitor. The ovarian cancer specimens we analyzed were derived from a recent clinical trial that compared the responses of patients with recurrent platinum-resistant ovarian cancer who received carboplatin plus the DNA methyltransferase inhibitor guadecitabine or a standard-of-care chemotherapy regimen selected by the treating physician. Tumor biopsies or malignant ascites were collected from patients before treatment (day 1, cycle 1) or after treatment (after 2 cycles) for epigenomic and transcriptomic profiling using the Infinium HumanMethyla-tion450 BeadChip (HM450). We defined 94 gene promoters that were hypomethylated significantly by guadecitabine, with 1,659 genes differentially expressed in pretreatment versus posttreatment tumors. Pathway analysis revealed that the experimental regimen significantly altered immune reactivation and DNA repair pathways. Progression-free survival correlated with baseline expression levels of 1,155 genes involved in 25 networks. In functional investigations in ovarian cancer cells, engineered upregulation of certain signature genes silenced by promoter methylation (DOK2, miR-193a, and others) restored platinum drug sensitivity. Overall, our findings illuminate how inhibiting DNA methylation can sensitize ovarian cancer cells to platinum drugs, in large part by altering gene expression patterns related to DNA repair and immune activation, with implications for improving the personalized care and survival outcomes of ovarian cancer patients. Significance: Epigenomic targeting may improve therapeutic outcomes in platinum-resistant and recurrent ovarian cancer in part by effects on DNA repair and antitumor immune responses.

UR - http://www.scopus.com/inward/record.url?scp=85041471047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041471047&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-17-1492

DO - 10.1158/0008-5472.CAN-17-1492

M3 - Article

C2 - 29229600

AN - SCOPUS:85041471047

VL - 78

SP - 631

EP - 644

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 3

ER -